

SEQUENCE LISTING

<110> Levinson, Arnold I.
Weiner, David B.
Otero, Miguel
Calarota, Sandra

<120> Vaccines for Suppressing IgE Mediated Allergic Disease and
Methods for Using the Same

<130> UPAP0024-500 (Penn 02725)

<160> 13

<170> PatentIn version 3.2

<210> 1
<211> 88
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 1
cccaagctta tggactggac ctggatcctc ttcttggtgg cagcagccac gcgagtccac 60
tccccatgggc tggctggcgg ctccgcgc 88

<210> 2
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 2
ccgctcgagc gtggggctgg aggacgttgg 30

<210> 3
<211> 87
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 3
ccgctcgaga gaaacgagct gtcgtaggat ccgatccaaa ttatttaagg actgattctg 60
ataaaagatag atttttacaa accatgg 87

<210> 4
<211> 88
<212> DNA
<213> Artificial Sequence

100

105

110

gtg cag cggttc tca gcc acg cgg cag ggg agg ccc cag acc tcc Val Gln Arg Phe Leu Ser Ala Thr Arg Gln Gly Arg Pro Gln Thr Ser 115 120 125	384
ctc gac tac acc aac gtc ctc cag ccc cac gcc aga gaa aaa aga gct Leu Asp Tyr Thr Asn Val Leu Gln Pro His Ala Arg Glu Lys Arg Ala 130 135 140	432
gtt gtt ggt tac gat cca aat tat tta agg act gat tct gat aaa gat Val Val Gly Tyr Asp Pro Asn Tyr Leu Arg Thr Asp Ser Asp Lys Asp 145 150 155 160	480
aga ttt tta caa acc atg gta aaa ctg ttt aac aga att aag aga gaa Arg Phe Leu Gln Thr Met Val Lys Leu Phe Asn Arg Ile Lys Arg Glu 165 170 175	528
aaa aga gct gtt gtt ggt ttt aat aat ttt acc gtt agc ttt tgg ttg Lys Arg Ala Val Val Gly Phe Asn Asn Phe Thr Val Ser Phe Trp Leu 180 185 190	576
agg gtt cct aaa gta tct gct agt cat tta gaa cat cat cat cat cat Arg Val Pro Lys Val Ser Ala Ser His Leu Glu His His His His His 195 200 205	624
cat tag His	630

<210> 6
<211> 209
<212> PRT
<213> Homo sapiens

<400> 6

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5 10 15
--

His Ser His Gly Leu Ala Gly Gly Ser Ala Gln Ser Gln Arg Ala Pro 20 25 30

Asp Arg Val Leu Cys His Ser Gly Gln Gln Gly Leu Pro Arg Ala 35 40 45

Ala Gly Gly Ser Val Pro His Pro Arg Cys His Cys Gly Ala Gly Arg 50 55 60

Ala Asp Trp Pro Gly Pro Pro Glu Leu Asp Val Cys Val Glu Glu Ala 65 70 75 80
--

Glu Gly Glu Ala Pro Trp Thr Trp Thr Gly Leu Cys Ile Phe Ala Ala 85 90 95

Ala Gly Gly Ser Val Pro His Pro Arg Cys His Cys Gly Ala Gly Arg
1 5 10 15

Ala Asp Trp Pro Gly Pro
20

<210> 9
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide

<400> 9

Glu Leu Asp Val Cys Val Glu Glu Ala Glu Gly Glu Ala Pro Trp
1 5 10 15

<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide

<400> 10

Glu Ala Pro Trp Thr Trp Thr Gly Leu
1 5

<210> 11
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> peptide

<400> 11

Thr Gly Leu Cys Ile Phe Ala Ala Leu Phe
1 5 10

<210> 12
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide

<400> 12